Dr. Goldberg on Precision Medicine in Hematologic Malignancies

Stuart L. Goldberg, MD
Published: Thursday, Mar 01, 2018



Stuart L. Goldberg, MD, chief medical officer, John Theurer Cancer Center, discusses precision medicine for patients with hematologic malignancies.

The goal of precision medicine is to give the right patient the right treatment, explains Goldberg. If the patient receives the right therapy, it will make their quality and longevity of life better, and no money will be wasted, Goldberg adds.

It has been estimated that one-third of medicine is wasted, says Goldberg. If physicians use precision medicine properly, their patients will benefit, see the true value of the drug, and will not receive lines of ineffective therapies.
 


Stuart L. Goldberg, MD, chief medical officer, John Theurer Cancer Center, discusses precision medicine for patients with hematologic malignancies.

The goal of precision medicine is to give the right patient the right treatment, explains Goldberg. If the patient receives the right therapy, it will make their quality and longevity of life better, and no money will be wasted, Goldberg adds.

It has been estimated that one-third of medicine is wasted, says Goldberg. If physicians use precision medicine properly, their patients will benefit, see the true value of the drug, and will not receive lines of ineffective therapies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Publication Bottom Border
Border Publication
x